Prospective analysis of low-level BCR-ABL1 T315I mutation in
CD34+ cells of patients with de novo chronic myeloid leukemia

J 2014

Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia

JURČEK, Tomáš; Filip RÁZGA; Petra MAZANCOVÁ; Milena MUSILOVÁ; Dana DVOŘÁKOVÁ et. al.

Základní údaje

Originální název

Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia

Autoři

JURČEK, Tomáš (203 Česká republika, garant); Filip RÁZGA (703 Slovensko, domácí); Petra MAZANCOVÁ (703 Slovensko, domácí); Milena MUSILOVÁ (203 Česká republika, domácí); Dana DVOŘÁKOVÁ (203 Česká republika, domácí); Marek BORSKÝ (203 Česká republika); Daniela ŽÁČKOVÁ (203 Česká republika, domácí); Blanka DOBEŠOVÁ (203 Česká republika); Lukáš SEMERÁD (203 Česká republika); Jiří MAYER (203 Česká republika, domácí) a Zdeněk RÁČIL (203 Česká republika, domácí)

Vydání

LEUKEMIA & LYMPHOMA, LONDON, INFORMA HEALTHCARE, 2014, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.891

Kód RIV

RIV/00216224:14110/14:00078457

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3109/10428194.2013.842988

UT WoS

000340224100035

EID Scopus

2-s2.0-84904874731

Klíčová slova anglicky

BCR-ABL1; T315I; CD34+; chronic myeloid leukemia

Štítky

EL OK, podil

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 1. 2015 12:37, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Th e detection of BCR – ABL1 kinase domain (KD) mutations is frequently associated with resistance to tyrosine kinase inhibitors (TKIs), which results in an impaired prognosis for patients with chronic myeloid leukemia (CML) [1]. Early detection of these mutations can potentially lead to early therapeutic intervention and optimization of an ongoing treatment strategy. Considering the hematopoiesis hierar- chy, it is expected that BCR – ABL1 mutation clones expand directly from hematopoietic stem cells or early progenitor cells [2]. It has already been reported that BCR – ABL1 KD mutations were detected in these cells before they occurred in bone marrow (BM) or peripheral blood (PB) [3]. Particu- lar focus should be given to the T315I mutation, which is resistant to all approved TKIs (imatinib, nilotinib and dasa- tinib) [4,5], meaning that early detection of this key BCR – ABL1 KD mutation in “ source ” cells could have potential clinical benefits.

Přiložené soubory

EL_1217003.pdf

Požádat o autorskou verzi souboru

Citovat

JURČEK, Tomáš; Filip RÁZGA; Petra MAZANCOVÁ; Milena MUSILOVÁ; Dana DVOŘÁKOVÁ; Marek BORSKÝ; Daniela ŽÁČKOVÁ; Blanka DOBEŠOVÁ; Lukáš SEMERÁD; Jiří MAYER a Zdeněk RÁČIL. Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia. LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2014, roč. 55, č. 8, s. 1915-1917. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2013.842988.

@article{1217003,
   author = {Jurček, Tomáš and Rázga, Filip and Mazancová, Petra and Musilová, Milena and Dvořáková, Dana and Borský, Marek and Žáčková, Daniela and Dobešová, Blanka and Semerád, Lukáš and Mayer, Jiří and Ráčil, Zdeněk},
   article_location = {LONDON},
   article_number = {8},
   doi = {http://dx.doi.org/10.3109/10428194.2013.842988},
   keywords = {BCR-ABL1; T315I; CD34+; chronic myeloid leukemia},
   language = {eng},
   issn = {1042-8194},
   journal = {LEUKEMIA & LYMPHOMA},
   title = {Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia},
   volume = {55},
   year = {2014}
}

TY  - JOUR
ID  - 1217003
AU  - Jurček, Tomáš - Rázga, Filip - Mazancová, Petra - Musilová, Milena - Dvořáková, Dana - Borský, Marek - Žáčková, Daniela - Dobešová, Blanka - Semerád, Lukáš - Mayer, Jiří - Ráčil, Zdeněk
PY  - 2014
TI  - Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia
JF  - LEUKEMIA & LYMPHOMA
VL  - 55
IS  - 8
SP  - 1915-1917
EP  - 1915-1917
PB  - INFORMA HEALTHCARE
SN  - 10428194
KW  - BCR-ABL1
KW  - T315I
KW  - CD34+
KW  - chronic myeloid leukemia
N2  - Th e detection of BCR – ABL1 kinase domain (KD) mutations is frequently associated with resistance to tyrosine kinase inhibitors (TKIs), which results in an impaired prognosis for patients with chronic myeloid leukemia (CML) [1]. Early detection of these mutations can potentially lead to early therapeutic intervention and optimization of an ongoing treatment strategy. Considering the hematopoiesis hierar- chy, it is expected that BCR – ABL1 mutation clones expand directly from hematopoietic stem cells or early progenitor cells [2]. It has already been reported that BCR – ABL1 KD mutations were detected in these cells before they occurred in bone marrow (BM) or peripheral blood (PB) [3]. Particu- lar focus should be given to the T315I mutation, which is resistant to all approved TKIs (imatinib, nilotinib and dasa- tinib) [4,5], meaning that early detection of this key BCR – ABL1 KD mutation in “ source ” cells could have potential clinical benefits.
ER  -

JURČEK, Tomáš; Filip RÁZGA; Petra MAZANCOVÁ; Milena MUSILOVÁ; Dana DVOŘÁKOVÁ; Marek BORSKÝ; Daniela ŽÁČKOVÁ; Blanka DOBEŠOVÁ; Lukáš SEMERÁD; Jiří MAYER a Zdeněk RÁČIL. Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia. \textit{LEUKEMIA \&{} LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2014, roč.~55, č.~8, s.~1915-1917. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2013.842988.

Přehled o publikaci